Ruti Aga and the Six-Year Ledger: A Forged Prescription That Killed the Defence That Could Have Worked

On a March morning at a label half marathon in China, Ruti Aga crossed the finish line first. The source report carries no name for the race, no time, no splits, no field depth. It records only that she won, and that an in-competition sample was taken afterwards. The sample returned methylprednisolone. She was provisionally suspended from 10 September, and by the Athletics Integrity Unit's statement on Thursday the sanction now stands at six years.

Six years. At thirty-two years of age. For a marathoner who won Tokyo in 2026 and holds three World Marathon Majors runner-up finishes. That number arrives as a single line in a bulletin and moves on. To me it is the place where the audit begins. In 2026, working as medical-staff liaison for the Chicago Fire in their expansion season, I kept a spiral ledger: twenty-seven first-team players, every treatment, every tight hamstring, every injection, logged by hand with a time and a clinician's initials. On 25 October the Fire beat D.C. United 2–0 at Soldier Field. Nobody asked for the ledger. I kept it because the club's injury reports were being phoned in from memory by people who had already left the building.

Aga's case demands that kind of ledger. What is written in it has less to do with a knee and more to do with paper.

Context: a runner, a calendar, a knee

Her record deserves restating because the performance component here is small and will be overstated. The source gives no personal best. From external recall — data pending verification — roughly 2:18:34 for second in Berlin 2026, and roughly 2:20:40 for the win in Tokyo 2026. The source does not say what she ran in the March race in China. The win is recorded; the mark is not. Where there is no mark, claiming form is fiction.

Consider the economics. A 2:18–2:20 Ethiopian woman has two revenue paths. The Majors — Tokyo, Berlin, Boston, London, Chicago, New York. And the Asian label circuit, where appearance fees are large, field depth is manageable, and weather risk is contained. The second path is less visible and pays more. That is the ground this case was built on.

Now the knee. According to the AIU statement, Aga attributed the methylprednisolone to a knee injury. Intra-articular or peri-articular glucocorticoid injection for knee synovitis in distance runners is ordinary sports-medicine practice. That fact does two jobs. It tells us the medical story was not absurd on its face. And it tells us the real failure was not in the story but in the paperwork.

Ethiopia's women's marathon depth is such that removing a 2:18 performer creates no measurable disturbance in selection arithmetic. So do not look at the competitive landscape for meaning here. Nothing changed there. What changed is the scaffolding around one athlete's body that we call medical support — and that, in this case, was absent.

Core: the classification, the arithmetic, the three verification failures

Start with the technical error in the source, because it distorts how the whole case gets read. Methylprednisolone is not an anabolic steroid. It is a glucocorticoid, WADA Prohibited List class S9. Anabolic steroids sit in S1. The source called it a prohibited steroid and stated that WADA classes it as performance enhancing. That is imprecise, and the imprecision matters, because S9 glucocorticoids are prohibited in-competition only, and only by injection, oral or rectal routes.

The consequence is that this case turns on route and timing, not on steroid use. A therapeutic knee injection given out-of-competition is entirely lawful. It becomes a violation only if residue is present during the in-competition window, which for a road race opens at 23:59 the day before the start. An injection days before the race gets caught. One given weeks earlier does not.

This puts me back on a Chicago evening in 2026, when a twenty-six-year-old central midfielder went down in the fourteenth minute of a reserve match. The club called it a lateral roll and cleared him in nine days. I sat with the physio and re-watched the mechanism: the foot was planted and externally rotated. That is a syndesmotic sprain, not a roll. He lasted twenty-two minutes on his return, then missed five weeks and eleven matches. After that I wrote mechanism before diagnosis — which direction the joint was loaded, at what minute, on what surface.

In this case, the mechanism is the whole case. The name of the drug is secondary; the route and the clock decide.

Aga had a legitimate defence, and the forged prescription destroyed it. Had the knee genuinely been treated and documented, the argument would have been about timing, route, and medical necessity. No-fault and no-significant-fault pathways were open. The presence sanction could have been reduced, or eliminated.

The arithmetic then reads plainly. Two years for presence, four for tampering, six in total. That is the Code's standard architecture. The two years indicate the panel treated methylprednisolone as a Specified Substance and set the period without proof of intent. The four years indicate tampering was treated as fully culpable. The total also indicates the panel declined the no-significant-fault mitigation that would have cut the presence period. Numbers do not lie about structure.

The third element is the real story. Per the AIU statement, the prescription was written by a family member with no medical registration, who claimed to have used an old prescription pad from a former workplace. The clinic named on the document did not exist.

Three independent verification failures, all of them checkable in isolation. The clinic did not exist. The person was not registered. The institution disowned the pad. Any one check surviving would have stopped this. This is where I apply my three-source rule, built in Chicago in 2026 when a twenty-nine-year-old outside back with 214 career appearances felt his Achilles pop in the sixty-first minute of a July friendly. The club's first statement said tightness. By the next morning I had three things: the club doctor's off-record read (full rupture, surgery Thursday), the agent confirming a second opinion in Milwaukee, and an imaging centre's appointment confirmation. All three agreed. I published the rupture eleven hours before the club did. The rule has held across roughly 190 injury stories since.

The AIU ran the same process in reverse. Three verifications, three failures. The difference is only in direction.

Fourth, a detail that gets lost: the tampering charge came from an interview, not from a document alone. Statements made under questioning. That matters because language and translation conditions in AIU interviews with East African athletes have been a recurring point of contention. It does not weaken the finding, since the documentary failures stand independently. But it explains where the six years came from — not from the drug, from the statement.

Fifth, scope. Standard AIU practice voids the result from the competition where the sample was collected, along with prize money and ranking points from that period. The source does not state whether the March result was formally annulled. What is clear is that results before 10 September are not automatically affected absent a finding of earlier use. The 2026 Tokyo title survives in her record. That sounds minor. In marathon history it is not, because when a ban ends, the record is all that remains.

Sixth, and to my mind the cleanest definition of this case: the TUE pathway was open and nobody walked down it. A properly managed athlete either documents the knee injection and files for a TUE, or observes the route-specific washout period and picks race dates accordingly. Neither happened. That absence is not coincidence. Where the infrastructure for producing documents does not exist, people fabricate documents.

Contrarian: six years is a paper sentence, not a drug sentence

Glucocorticoids have no proven endurance performance benefit. They reduce inflammation and pain, which makes them the cheapest, most available tool for masking injury. This is not a performance-enhancing drug; it is a performance-tolerating one. An athlete who takes it does not run faster. She runs at all. Missing that distinction is the root of the error in the source, and it is why this case will be wrongly filed alongside anabolic cases.

The sanction is not for the drug. It is for the lie. And the lie came from an athlete with no visible institutional support: a prescription written by a relative, an old pad, a clinic that does not exist. That is not the blueprint of a sophisticated network. It is the blueprint of panic. An athlete inside a professional doping structure has better paper than this. Here there was a knee, a pain, a race date, and no doctor.

Then the asymmetry. This outcome will be read two ways. As evidence of AIU rigour, and as evidence that the same rigour lands harder on athletes without lawyers, media advisers and TUE files. I do not dismiss that question, but I refuse to ask it badly. The gap in sanctions usually comes from the quality of documentation, not from geography. Good paper gets a shorter sentence. No paper produces forged paper, and forged paper gets six years. That is a system weakness, and it does not excuse the athlete's choice.

One more thing a team doctor liaison hears that the press release leaves out: the knee was probably real. The pain was real. The need for treatment was real. Only the paper was fake. Collapsing that distinction is easy and many will do it, calling the injury an excuse. In my experience excuses are usually built on top of real injuries, not on empty space. Denying an injury and forging its paperwork come from the same fear — the fear of a calendar.

And that is where six years shows its true face. It is a calendar sentence. Six years from thirty-two means a return at thirty-eight, in a national depth chart where a thirty-eight-year-old with a doping record is functionally unselectable. The ban swallows the 2028 Olympic cycle whole. Five weeks is not a diagnosis; it is a question with a calendar attached. Six years is not a diagnosis either. It is a sentence a panel writes and a career reads.

What the documents do not say

Absence is evidence. The source carries no statement from the Ethiopian federation — only the AIU. There is no recorded investigation into the role of an agent or management, though someone must have been in the path of that document. The year of the March race is not stated, nor the end date of the ban. Provisional suspension from 10 September with the ban backdated to it is a procedural benefit, not a reduction; the athlete gains nothing real. A CAS appeal window will exist, typically around twenty-one days from the reasoned decision, but a document-based tampering finding is hard to overturn.

Medical privacy and administrative delay need to be kept separate from concealment. Not every delay is a conspiracy and not every silence is a crime. In this case tampering was established because three independent checks failed — clinic, registration, pad. That is the standard I hold, and I apply it to everyone. Where all three are missing, I write that the body has not confirmed it, and move on.

Takeaway

The useful lesson here is not about the drug. It is about how an injury, a calendar and an absent doctor add up to six years. The next time an Ethiopian or Kenyan runner phones an agent about knee pain before a Chinese label race, I would like the answer to be a TUE form rather than a prescription pad. If it is not, the next ledger entry will read the way this one does: the paper ledger says the prescription exists; the clinic says it does not. Injury news travels fast; injury truth travels with paperwork. The only open question is whose hands that paperwork will be in next.